Scale-up evaluation of a composite tumor marker assay for the early detection of renal cell carcinoma

Dong Su Kim, Won Sik Ham, Won Sik Jang, Kang Su Cho, Young Deuk Choi, Suki Kang, Bora Kim, Kook Jin Kim, Eun Ji Lim, Sun Young Rha, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Chang Wook Jeong, Nam Hoon Cho

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


The early detection of renal cell carcinoma (RCC) using tumor markers remains an attractive prospect for the potential to downstage the disease. To validate the scale-up clinical performance of potential tumor markers for RCC (as a single marker and as a composite tumor marker composed of nicotinamide N-methyltransferase (NNMT), L-Plastin (LCP1), and non-metastatic cells 1 protein (NM23A)), the scale-up assay was performed. Patients with RCC from multiple domestic institutes were included in the clinical evaluation for reassessment and improvement of the established triple markers of our product. For the diagnostic performance of the composite markers, the best-split cutoff points of each marker (147 pg/mL for NNMT, 1780 pg/mL for LCP1, and 520 pg/mL for NM23A) were installed. Serum levels of NNMT, LCP1, and NM23A were greatly increased in subjects with RCC (p < 0.0001). In 1042 blind sample tests with control individuals (n = 500) and patients with RCC (n = 542), the diagnostic sensitivity and specificity of the composite three-marker assay were 0.871 and 0.894, respectively, and the resulting AUC (Area under Curve) of ROC (Receiver Operating Characteristic) was 0.917. As a single marker, the diagnostic accuracies of NNMT, LCP1, and NM23A, as estimated by ROC, were 0.833, 0.844, and 0.601, respectively. The composite three-marker assay with NNMT, LCP1, and NM23A is a more improved novel serum marker assay for the early detection of RCC in cases of renal mass or unknown condition. The NNMT, LCP1, and NM23A triple marker assay could be a powerful diagnostic tumor marker assay to screen the early stage of RCC.

Original languageEnglish
Article number750
Issue number10
Publication statusPublished - 2020 Oct

Bibliographical note

Funding Information:
Acknowledgments: The biospecimens and data used in this study were provided by the Biobank of Seoul National University Hospital, Chonnam National University Hwasun Hospital, Ajou University Human Bio-Resource Bank (AHBB), National Biobank of Korea-Kyungpook National University Hospital (KNUH), Gyeongsang National University Hospital, Jeju University Hospital, and Chonbuk National University Hospital, a member of the Korea Biobank Network, which is supported by the Ministry of Health and Welfare. All samples derived from the Korea Biobank Network were obtained with informed consent under institutional review board-approved protocols. The specimens used for this study were distributed by the Korea Institute of Radiological and Medical Sciences (KIRAMS) Radiation Biobank (KRB) in the Republic of Korea.

Funding Information:
Funding: This study was supported by the Korea Health Technology Research and Development Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (Grant number: HI17C1792).

Publisher Copyright:
© 2020 by the authors.

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry


Dive into the research topics of 'Scale-up evaluation of a composite tumor marker assay for the early detection of renal cell carcinoma'. Together they form a unique fingerprint.

Cite this